1. Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2
- Author
-
Ulkan Kilic, H. Xing, Dirk M. Hermann, Claudio L. Bassetti, Ertugrul Kilic, and Z. Wang
- Subjects
Brain Infarction ,Male ,Time Factors ,Statin ,Nitric Oxide Synthase Type III ,medicine.drug_class ,Blotting, Western ,Ischemia ,Nitric Oxide Synthase Type II ,Cell Count ,Reductase ,Pharmacology ,Neuroprotection ,Brain Ischemia ,Mice ,medicine.artery ,Laser-Doppler Flowmetry ,medicine ,Animals ,Rosuvastatin ,Rosuvastatin Calcium ,Stroke ,Mitogen-Activated Protein Kinase 1 ,Sulfonamides ,Mitogen-Activated Protein Kinase 3 ,Dose-Response Relationship, Drug ,Staining and Labeling ,business.industry ,General Neuroscience ,nutritional and metabolic diseases ,Infarction, Middle Cerebral Artery ,medicine.disease ,Fluorobenzenes ,Mice, Inbred C57BL ,Pyrimidines ,Biochemistry ,Reperfusion ,Middle cerebral artery ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Nitric Oxide Synthase ,business ,medicine.drug - Abstract
After recent clinical trials, statins have gained increasing significance in secondary stroke prevention. From experimental studies, it is well established that statins have beneficial action when delivered prophylactically prior to a stroke. Conversely, much less is known about the effects of statins on injury development when delivered after ischemia. We here examined the effects of a post-ischemic delivery of rosuvastatin (0.5, 5 or 20 mg/kg, administered i.p. immediately after reperfusion onset), a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on brain injury and cell signaling after focal cerebral ischemia, induced by 90 min of intraluminal middle cerebral artery occlusion in mice. In animals receiving normal saline, 0.5 or 5 mg/kg rosuvastatin, middle cerebral artery occlusions resulted in reproducible brain infarcts at 24 h after reperfusion onset, which did not differ in size. However, rosuvastatin, administered at higher doses (20 mg/kg), reduced infarct volume at 24 and 48 h after ischemia (by 34+/-16% and 18+/-3%, respectively, P
- Published
- 2005
- Full Text
- View/download PDF